Fulgent Genetics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FLGT research report →
Range $19 – $19
Price Chart
About the company
Fulgent Genetics, Inc. , together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units.
- CEO
- Ming Hsieh
- IPO
- 2016
- Employees
- 1,315
- HQ
- El Monte, CA, US
Get TickerSpark's AI analysis on FLGT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $673.89M
- P/E
- -7.81
- PEG
- 0.12
- P/S
- 2.04
- P/B
- 0.67
- EV/EBITDA
- -8.16
- Div Yield
- 0.00%
- Gross Margin
- 33.82%
- Op Margin
- -38.55%
- Net Margin
- -27.53%
- ROE
- -8.76%
- ROIC
- -11.74%
Latest fiscal year · YoY change
- Revenue
- $322.67M+13.8%
- Gross Profit
- $130.88M+22.1%
- Op Income
- $-91,096,000
- Net Income
- $-60,513,000-41.7%
- EPS
- $-1.97-39.7%
- OCF Growth
- -582.6%
- FCF Growth
- -545.1%
- 52W High
- $31.04
- 52W Low
- $13.46
- 50D MA
- $21.75
- 200D MA
- $19.10
- Beta
- 1.00
- RSI (14)
- 57
- Avg Volume
- 330.30K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Fulgent reported higher Q3 revenue and improved margins, helped by Bako/StrataDx integration and better collections, while reaffirming full-year revenue and raising cash and EPS outlooks.· November 5, 2026
- Q3 revenue was $90.4 million, up 8% year over year and 6% sequentially, with growth driven mainly by Bako Diagnostics and StrataDx integration.
- GAAP gross margin was 35.3% and non-GAAP gross margin was 36.3%; management said better collection rates helped margins and that more improvement is possible as billing work continues.
- GAAP loss improved to $13.2 million, or $0.48 per share, from a $29.5 million loss in Q2; non-GAAP loss was about $2.4 million, or $0.09 per share.
- The company reaffirmed full-year revenue guidance of $330 million to $340 million and raised full-year 2026 non-GAAP EPS guidance to a loss of $1.65 to $1.75 per share.
- Cash increased to about $652.4 million after a $112.3 million federal tax refund, and year-end cash is now expected to be about $630 million, up from prior guidance of $610 million.
Revenue in Q3 was $90.4 million, up 8% year over year and 6% sequentially, including $21.8 million from Bako Diagnostics and StrataDx versus $16.4 million in Q2. Segment revenue was Precision Diagnostics $41.8 million, down 18% year over year but up 1% sequentially; Anatomic Pathology $40.9 million, up 57% year over year and 9% sequentially; and Biopharma Services $7.7 million, up 5% year over year and 19% sequentially. GAAP gross margin was 35.3% and non-GAAP gross margin was 36.3%; GAAP operating margin was -24.9% versus -42.3% in Q2, and non-GAAP operating margin was -13.2% versus -26.2%. GAAP loss was $13.2 million, or $0.48 per share, versus a $29.5 million loss in Q2; non-GAAP loss was about $2.4 million, or $0.09 per share; adjusted EBITDA loss was about $7.5 million versus $17.1 million in Q2. Cash, cash equivalents, restricted cash and marketable securities were about $652.4 million, up $100.9 million sequentially, mainly from a $112.3 million federal tax refund and related interest. Full-year 2026 revenue guidance was reaffirmed at $330 million to $340 million, with Precision Diagnostics expected at $161 million to $165 million, Anatomic Pathology at $146 million to $150 million, and Biopharma Services at $23 million to $25 million. Full-year non-GAAP gross margin is expected in the mid-30% range and non-GAAP operating margin in the low negative 20s range. Full-year 2026 non-GAAP loss guidance was raised to $1.65 to $1.75 per share from $2.22 to $2.35 per share, and year-end cash is now expected at about $630 million.
Ming Hsieh emphasized momentum in the therapeutic development pipeline and said the company is seeing encouraging clinical data from its proprietary nano drug delivery platform. He highlighted progress for FID-007, including completion of most of Phase 2, an FDA end-of-Phase-2 meeting in August, and preparation for Phase 3, while noting FID-022 remains in Phase 1 dose escalation with maximum tolerated dose expected in the first half of next year. On the lab side, he said AI and digital pathology adoption is accelerating and that the company is using these tools to improve efficiency, quality, and future gross margin expansion.
Paul Kim focused on the quarter’s financial improvement and the mechanics behind it. He said Q3 revenue reached $90.4 million, GAAP gross margin was 35.3%, non-GAAP gross margin was 36.3%, and operating expenses declined, helping improve GAAP and non-GAAP operating margins and reduce the quarterly loss. He also pointed to the $112.3 million tax refund, the increase in ending cash forecast from $610 million to $630 million, and the improved full-year non-GAAP EPS outlook to a loss of $1.65 to $1.75 per share. He said the company expects gross margins to normalize as collections return to historical levels and noted ongoing investment in R&D, integration, and infrastructure.
Analysts focused on the billing and revenue cycle management transition, asking how far along it is, whether current collection rates are still below historical levels, and whether any revenue improvement reflects catch-up claims. Management said it is still “deep into the game,” with several customizations implemented, but that more fine-tuning remains; they said the improved Q3 collection rate came faster than expected and that there is still room for gross margins to grind higher. On Q4, management said the revenue guide implies room for sequential improvement if they perform toward the high end of the range, and they described seasonality as less pronounced given the business mix. They also said AI modules are expected to improve productivity and quality, and that Bako integration is progressing as they cross-sell and consolidate operations.
The call showed improving execution in the core lab business, with better collections, higher gross margin, lower expenses, and a raised EPS outlook. Management also sounded constructive on AI-driven workflow gains and on the therapeutic pipeline, especially the progress on FID-007 and FID-022.
Management acknowledged the billing and RCM transition is not finished and still requires additional fine-tuning, with gross margins expected to normalize as collection rates return to historical levels. The therapeutic pipeline remains early-stage and capital-intensive, and the company said it still needs to provide more detail later this year on FID-007 while FID-022 is only in Phase 1 dose escalation.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 61.3%
- Shares Outstanding
- 27.94M
- Float Shares
- 17.12M
of shares held by institutions
147 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 2.44M | ▲ 153.12K |
| Vanguard Group Inc | 1.26M | ▲ 80.76K |
| Acadian Asset Management LLC | 1.09M | ▲ 73.04K |
| Jacobs Levy Equity Management, Inc | 782.12K | ▲ 425.76K |
| Vanguard Capital Management LLC | 765.87K | ▼ 23.63K |
| Diametric Capital, LP | 697.78K | ▲ 336.74K |
| Ameriprise Financial Inc | 670.08K | ▲ 106.71K |
| Dimensional Fund Advisors LP | 646.63K | ▲ 21.27K |
| State Street Corp | 516.94K | ▲ 18.27K |
| Jpmorgan Chase & Co | 516.11K | ▼ 240.45K |
| Invenomic Capital Management LP | 498.29K | ▼ 112.03K |
| Geode Capital Management, LLC | 438.35K | ▼ 82.66K |
Held by 178 ETFs
Biggest fund positions in FLGT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 26, 26 | Gao Hanlin | other | 1,645 |
| Oct 26, 26 | Xie Jian | other | 4,361 |
| Oct 26, 26 | Kim Paul | other | 2,748 |
| Sep 1, 26 | Kim Paul | other | 2,087 |
| Sep 1, 26 | Hsieh Ming | other | 4,392 |
| Sep 2, 26 | Gao Hanlin | sell | 1,673 |
| Sep 2, 26 | Xie Jian | sell | 2,127 |
| Aug 26, 26 | Hsieh Ming | other | 2,949 |
| Aug 26, 26 | Kim Paul | other | 1,168 |
| Aug 27, 26 | Xie Jian | sell | 1,193 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FLGT coverage
Recent articles, reports, and earnings notes.
No research on FLGT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FLGT report →Fulgent Genetics (FLGT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
zacks.com · Nov 18
Fulgent: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 17
Fulgent Genetics, Inc. (FLGT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
What Fulgent Genetics (FLGT) Said on Its Q3 Earnings Call
marketbeat.com · Nov 5
Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 5
Fulgent Reports Third Quarter 2026 Financial Results
businesswire.com · Nov 5
Head to Head Survey: Agilon Health (NYSE:AGL) and Fulgent Genetics (NASDAQ:FLGT)
defenseworld.net · Oct 18
Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026
businesswire.com · Oct 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.